Copy to clipboard 
Zimmer Biomet reported 1Q25 orthopedic sales of $1.9 billion, up 1.1% compared to the first quarter of 2024.
Hip replacement sales in the U.S. and sports medicine were highlights in the quarter. The combination of Z1 hip stem, HAMMR surgical impactor and OrthoGrid navigation allowed the company to get back to offense within hip replacement. Roughly half of the Z1 users came from competitive accounts, according to Zimmer Biomet.
In general, however, the company’s underwhelming performance in the U.S. has necessitated change. Zimmer Biomet plans to elevate its U.S. performance by evolving its sales channel.
“You cannot grow the U.S. new business 0.2%,” said Zimmer Biomet CEO Ivan Tornos. “So, we’re making changes in terms of leaders, quantity of territories and the incentive plan. As a result of the lack of growth, certain individuals will be exiting the organization fairly soon. We’re going to be deploying more people into S.E.T. We know we can do better in robotics if we add the right quantity and quality of individuals. We’re going to add additional people in the ASC environment.”
The company completed its acquisition of Paragon 28 in late April 2025. It plans to keep key executives in place, signed on the entire Paragon 28 sales force and will keep Paragon 28’s design processes separate for the time being to minimize disruption for the fast growing foot and ankle asset.
Inclusive of Paragon 28 and estimated tariff impact, Zimmer Biomet expects 2025 total revenue sales growth between 5.7% and 8.2%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,405.5 | $1,389.3 | $16.1 | 1.2% |
| Knees | $792.9 | $788.1 | $4.8 | 0.6% |
| Hips | $495.7 | $491.1 | $4.6 | 0.9% |
| Extremities | $116.8 | $110.1 | $6.7 | 6.1% |
| Trauma | $166.7 | $159.2 | $7.5 | 4.7% |
| Sports Medicine | $51.8 | $47.5 | $4.2 | 8.9% |
| Orthobiologics | $33.5 | $32.8 | $0.7 | 2.2% |
| Enabling Technology | $22.5 | $23.6 | ($1.1) | (4.7%) |
| Other | $229.2 | $236.8 | ($7.6) | (3.2%) |
| Total | $1,909.1 | $1,889.3 | $19.8 | 1.1% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,113.6 | $1,099.6 | $14.0 | 1.3% |
| OUS | $795.5 | $789.7 | $5.9 | 0.7% |
| EMEA | $458.2 | $444.8 | $13.4 | 3% |
| APAC | $253.0 | $258.0 | ($5.0) | (2%) |
| ROW | $84.4 | $86.9 | ($2.5) | (2.9%) |
| Total | $1,909.1 | $1,889.3 | $19.8 | 1.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,909.1 | |
| Cost of Sales | $549.8 | 28.8% |
| Selling and Admin | $758.8 | 39.7% |
| R & D | $110.6 | 5.8% |
| R & D | $110.6 | 5.8% |
| Other | $307.3 | 16.1% |
Zimmer Biomet reported 1Q25 orthopedic sales of $1.9 billion, up 1.1% compared to the first quarter of 2024.
Hip replacement sales in the U.S. and sports medicine were highlights in the quarter. The combination of Z1 hip stem, HAMMR surgical impactor and OrthoGrid navigation allowed the company to get back to offense within hip...
Zimmer Biomet reported 1Q25 orthopedic sales of $1.9 billion, up 1.1% compared to the first quarter of 2024.
Hip replacement sales in the U.S. and sports medicine were highlights in the quarter. The combination of Z1 hip stem, HAMMR surgical impactor and OrthoGrid navigation allowed the company to get back to offense within hip replacement. Roughly half of the Z1 users came from competitive accounts, according to Zimmer Biomet.
In general, however, the company’s underwhelming performance in the U.S. has necessitated change. Zimmer Biomet plans to elevate its U.S. performance by evolving its sales channel.
“You cannot grow the U.S. new business 0.2%,” said Zimmer Biomet CEO Ivan Tornos. “So, we’re making changes in terms of leaders, quantity of territories and the incentive plan. As a result of the lack of growth, certain individuals will be exiting the organization fairly soon. We’re going to be deploying more people into S.E.T. We know we can do better in robotics if we add the right quantity and quality of individuals. We’re going to add additional people in the ASC environment.”
The company completed its acquisition of Paragon 28 in late April 2025. It plans to keep key executives in place, signed on the entire Paragon 28 sales force and will keep Paragon 28’s design processes separate for the time being to minimize disruption for the fast growing foot and ankle asset.
Inclusive of Paragon 28 and estimated tariff impact, Zimmer Biomet expects 2025 total revenue sales growth between 5.7% and 8.2%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,405.5 | $1,389.3 | $16.1 | 1.2% |
| Knees | $792.9 | $788.1 | $4.8 | 0.6% |
| Hips | $495.7 | $491.1 | $4.6 | 0.9% |
| Extremities | $116.8 | $110.1 | $6.7 | 6.1% |
| Trauma | $166.7 | $159.2 | $7.5 | 4.7% |
| Sports Medicine | $51.8 | $47.5 | $4.2 | 8.9% |
| Orthobiologics | $33.5 | $32.8 | $0.7 | 2.2% |
| Enabling Technology | $22.5 | $23.6 | ($1.1) | (4.7%) |
| Other | $229.2 | $236.8 | ($7.6) | (3.2%) |
| Total | $1,909.1 | $1,889.3 | $19.8 | 1.1% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,113.6 | $1,099.6 | $14.0 | 1.3% |
| OUS | $795.5 | $789.7 | $5.9 | 0.7% |
| EMEA | $458.2 | $444.8 | $13.4 | 3% |
| APAC | $253.0 | $258.0 | ($5.0) | (2%) |
| ROW | $84.4 | $86.9 | ($2.5) | (2.9%) |
| Total | $1,909.1 | $1,889.3 | $19.8 | 1.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,909.1 | |
| Cost of Sales | $549.8 | 28.8% |
| Selling and Admin | $758.8 | 39.7% |
| R & D | $110.6 | 5.8% |
| R & D | $110.6 | 5.8% |
| Other | $307.3 | 16.1% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
